Antiretroviral Therapy Reduces HIV Transmission in Discordant Couples in Rural Yunnan, China

Na He¹, Song Duan², Yingying Ding¹, Keming Rou³, Jennifer M. McGoogan⁵, Manhong Jia⁴, Yuecheng Yang², Jibao Wang², Julio S. G. Montaner⁵, Zunyou Wu³*, for the China National HIV Prevention Study Group*

¹Department of Epidemiology, School of Public Health, and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China, ²Dehong Prefecture Center for Disease Control and Prevention, Mangshi, Yunnan Province, China, ³National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Beijing, China, ⁴Yunnan Provincial Center for Disease Control and Prevention, Kunming, Yunnan Province, China, ⁵British Colombia Centre for Excellence in HIV/AIDS, St Paul’s Hospital, and Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, Canada

Abstract

Background: Although HIV treatment as prevention (TasP) via early antiretroviral therapy (ART) has proven to reduce transmissions among HIV-serodiscordant couples, its full implementation in developing countries remains a challenge. In this study, we determine whether China’s current HIV treatment program prevents new HIV infections among discordant couples in rural China.

Methods: A prospective, longitudinal cohort study was conducted from June 2009 to March 2011, in rural Yunnan. A total of 1,618 HIV-discordant couples were eligible, 1,101 were enrolled, and 813 were followed for an average of 1.4 person-years (PY). Routine ART was prescribed to HIV-positive spouses according to eligibility (CD4<350 cells/µl). Seroconversion was used to determine HIV incidence.

Results: A total of 17 seroconversions were documented within 1,127 PY of follow-up, for an overall incidence of 1.5 per 100 PY. Epidemiological and genetic evidence confirmed that all 17 seroconverters were infected via marital secondary sexual transmission. Having an ART-experienced HIV-positive partner was associated with a lower rate of seroconversion compared with having an ART-naïve HIV-positive partner (0.8 per 100 PY vs. 2.4 per 100 PY, HR = 0.34, 95%CI = 0.12–0.97, p = 0.0436). While we found that ART successfully suppressed plasma viral load to <400 copies/ml in the majority of cases (85.0% vs. 19.5%, p<0.0001 at baseline), we did document five seroconversions among ART-experienced subgroup.

Conclusions: ART is associated with a 66% reduction in HIV incidence among discordant couples in our sample, demonstrating the effectiveness of China’s HIV treatment program at preventing new infections, and providing support for earlier ART initiation and TasP implementation in this region.

Introduction

At the end of 2011, approximately 780,000 people were living with HIV/AIDS and heterosexual transmission remained the primary mode of transmission in 47% of cases in China [1]. We also witnessed a rise in proportion of new infections in people that engage in stable, HIV-serodiscordant relationships. Hence, individuals in serodiscordant relationships represent a growing high-risk population [1–5].

Antiretroviral therapy (ART) is increasingly recognized as a very promising strategy for reducing HIV transmission among discordant couples [6,7]. Effective viral suppression through ART has been associated with a significant reduction in infectivity and therefore diminished risk of HIV transmission in studies conducted in North America [8,9], Africa [5,10,11], Europe [12], and South America [13]. The benefit of ART in preventing new HIV infections has been confirmed by the HIV Prevention Trials Network (HPTN) 052 study, a two-arm, multi-site (nine countries) randomized trial on the effectiveness of treatment strategies among serodiscordant couples, which found that early initiation of ART results in a 96% reduction in sexual transmission [14].

Conclusive evidence for HIV treatment as prevention (TasP) represents a major victory in the fight against HIV/AIDS. However, broad-scale implementation of this strategy is expected to be expensive and challenging [7,13,16]. A recent study that was conducted in rural China found no benefit of ART in reducing...
transmission in discordant couples, further highlighting the challenges to effective TasP implementation in the real world [17,18].

In 2002, China launched its National Free Antiretroviral Treatment Program (NFATP), and the program has expanded rapidly nationwide since 2003. By the end of 2009, treatment coverage for eligible patients had increased to 63% and mortality had decreased to less than 20 deaths per 100 person-years (PY) [19,20]. Coverage for eligible patients has since expanded even further to 74% by the end of 2011 [1]. Although there have been substantial improvements in the provision of treatment services to HIV-positive patients in China, challenges remain, which include the rapid increase in the number of HIV-positive individuals that progress from HIV infection to clinical AIDS stage, and the considerable numbers of HIV-infected individuals who are eligible for treatment but have not been provided with ART, particularly among HIV-discordant couples [1]. In this study, we aimed to test the hypothesis that China’s current HIV treatment program prevents new infections among discordant, heterosexual couples.

Methods

Study site and participants

A prospective, longitudinal cohort study that assessed the HIV incidence and its determinants among HIV-discordant couples was conducted from June 2009 to March 2011 in Dehong, Yunnan. Dehong is an autonomous prefecture in Western Yunnan bordering Myanmar that is one of the regions most affected by HIV in China [21,22]. All previously identified HIV-discordant couples in Dehong were invited to participate in the study. Each participant was asked to return for one follow-up visit 12 months after the baseline survey, before March 2011. HIV-positive partners were eligible for the study if they were confirmed to a) have an AIDS diagnosis or HIV-positive status, b) be 18 years or older, c) reside in the selected town, and d) have a sero-negative spouse residing in the selected town. HIV-negative partners were eligible for the study if they were confirmed to a) have an HIV-negative status, b) be 18 years or older, c) reside in the selected town, and d) have a sero-positive spouse residing in the selected town. It should be noted that all HIV-negative partners have been informed of the positive status of the index partner within one month after confirmation of HIV-positive status, as a requirement of Yunnan Provincial HIV/AIDS Prevention and Treatment Regulation that was issued in 2006 [23]. A flow chart describing the development of our cohort of HIV-discordant couples can be found in Figure 1.

Antiretroviral treatment

Routine ART was prescribed for HIV-positive partners in accordance with China’s national guidelines, i.e., initiation of ART was primarily based on a patient’s CD4 level or clinical stages, and none of the HIV-positive patients were treated specifically because of their serodiscordance status. Prior to 2008, the eligible criteria for initiating ART include all patients with CD4≤200 cells/μl, or patient reaching WHO clinical stage 3 or 4. The criteria were then modified to include those with CD4≤350 cells/μl in 2008 [20]. Therefore, some HIV-positive partners included in this study began ART earlier than others. Furthermore, some HIV-positive partners who were not on ART at baseline started ART during the follow-up period. Only those who started ART before the midpoint of the follow-up period were classified as ART-experienced group. Those who started ART after the midpoint of the follow-up period were still classified as ART-Naive group, given the fact that it usually takes 3 to 6 months to achieve viral suppression among patients who take ART.

Data and sample collection

At baseline and at follow-up visit, each participant was interviewed face-to-face by a trained and experienced public health professional in a private place using a structured questionnaire. Both HIV-positive and HIV-negative spouses were asked about their demographic characteristics and their sexual and drug use behaviors. Frequency of condom use with their HIV-positive partner in the past 12 months was indicated as “never”, “sometimes”, “nearly always”, or “every time” and recoded as inconsistent (never, sometimes, or nearly always) vs. consistent (every time). At each visit, 10 ml venous blood samples were collected from each participant. Plasma was extracted and stored at −70°C for later HIV-1, syphilis, herpes simplex virus 2 (HSV-2), CD4, and viral load testing as well as HIV genotype and phylogenetic analysis.

HIV-1, syphilis, and HSV-2, CD4, and viral load testing

HIV testing was performed using a commercially-available ELISA (Kehua Biotech, China). All samples that screened positive for HIV were confirmed by Western blot (Genelabs Diagnostics, Singapore). Testing for syphilis was performed using a rapid plasma reagent (RPR) test (Kehua Biotech, China) with confirmation by TREPOMENA pallidum particle agglutination assay (TPHA, Lizhu Biological Medicine, China). Subjects with plasma positive for syphilis in both RPR and TPHA tests were determined to be currently infected with syphilis. HSV-2 IgG antibody testing was performed using the Capita anti-HSV-2 IgG ELISA (Trinity Biotech, Ireland). CD4+ T cell counts were measured by FACSCount (Becton Dickinson, USA). HIV viral load was measured with the NucliSENS EasyQ HIV-1 assay (Biomerieux, France), which had a lower detection limit (LDL) of 50 copies/ml. All tests were performed according to manufacturers’ instructions.

HIV genotype and phylogenetic analysis

RNA extraction, RT-PCR amplification, and nucleotide sequencing were performed in physically separated laboratories. Viral RNA was extracted using the Viral RNA Extraction Mini Kit (Roche, USA). Extracted RNA was reverse-transcribed into cDNA, which was used as the template for PCR amplification of the HIV-1 pol gene by nested PCR (Takara Biotechnology, China). Primers and PCR conditions have been previously described [24–26]. PCR products were sequenced using the ABI PRISM 3730XL DNA Analyzer (Applied Biosystems, USA).

Nucleotide sequences of amplified pol regions from all HIV-positive participants together with other non-clustered control sequences were aligned using the ClustalX program in MEGA software version 5.0. Phylogenetic and molecular evolutionary analyses were conducted using MEGA software version 5.0. Evolutionary distances were calculated using Kimura two-parameter modeling, excluding positions with alignment gaps in any sequence. Phylogenetic dendrograms were constructed using the neighbor-joining method with Kimura two-parameter modeling. The reliability of each node was evaluated by bootstrapping with 2,000 replicates.

Statistical analysis

Chi-square test and Fisher’s exact test were used to compare categorical variables. HIV incidence was calculated by using the number of persons who seroconverted as the numerator and the amount of HIV-seronegative time in follow-up as the denomina-
tor. Those who did not seroconvert contributed follow-up time until the study end date. Those who were found to have seroconverted during follow-up were assumed to have seroconverted at the midpoint between baseline and follow-up visit, thus they contributed follow-up time until this midpoint date. Poisson 95% confidence intervals (CIs) were calculated for overall incidence and for subgroup comparisons.

Univariate and multivariate Cox proportional hazards regression models were used to examine factors associated with seroconversion. In multivariate analysis, we included demographic variables and those variables with p-values less than 0.1 in univariate analyses and with forced entry of HSV-2 status and frequency of sex in past 12 months. Plasma viral load and condom use variables were not adjusted in the multivariate model because they were most likely to be consequences of ART. A sensitivity analysis was performed by additionally adjusting multivariate regression models for the variable “plasma viral load”. The variable “Consistent condom use in past 12 months” was not

Figure 1. Flow chart depicting the development of the cohort of HIV-discordant couples who participated in this study of HIV discordant couples in rural Yunnan, China, 2009–2011.
doi:10.1371/journal.pone.0077981.g001
Table 1. Baseline characteristics of those retained in the cohort and lost to follow-up among study of HIV discordant couples in rural Yunnan, China, 2009–2011.

| Characteristics                         | Retained in Cohort N (%) | Lost to Follow-up N (%) | P-value |
|-----------------------------------------|--------------------------|-------------------------|---------|
| **HIV-negative partners at baseline**   |                          |                         |         |
| Age (years)                             |                          |                         |         |
| <30                                     | 233 (28.6)               | 80 (27.8)               | 0.9380  |
| 30–39                                   | 338 (41.6)               | 123 (42.7)              |         |
| ≥40                                     | 242 (29.8)               | 85 (29.5)               |         |
| Gender                                  |                          |                         |         |
| Female                                  | 646 (79.5)               | 220 (76.4)              | 0.2746  |
| Male                                    | 167 (20.5)               | 68 (23.6)               |         |
| Education                               |                          |                         |         |
| Illiterate or primary school            | 560 (68.9)               | 203 (70.5)              | 0.6117  |
| Junior/middle or high school            | 253 (31.1)               | 85 (29.5)               |         |
| History of any drug use                 |                          |                         |         |
| No                                      | 787 (96.8)               | 279 (96.9)              | 0.9516  |
| Yes                                     | 26 (3.2)                 | 9 (3.2)                 |         |
| History of injecting drug use           |                          |                         |         |
| No                                      | 808 (99.4)               | 285 (99.0)              | 0.4638  |
| Yes                                     | 5 (0.6)                  | 3 (1.0)                 |         |
| Injecting drug use in past 12 months    |                          |                         |         |
| No                                      | 812 (99.9)               | 288 (100.0)             | 0.5515  |
| Yes                                     | 1 (0.1)                  | 0 (0.0)                 |         |
| Frequency of sex in past 12 months      |                          |                         |         |
| No sex                                  | 73 (9.1)                 | 51 (18.2)               | 0.0002  |
| 1–3                                     | 314 (39.1)               | 99 (35.4)               |         |
| 4–30                                    | 417 (51.9)               | 130 (46.4)              |         |
| Consistent condom use in past 12 months |                          |                         |         |
| No sex                                  | 73 (9.1)                 | 51 (18.2)               | <0.0001 |
| No                                      | 182 (22.2)               | 70 (25.0)               |         |
| Yes                                     | 549 (68.3)               | 159 (56.8)              |         |
| Syphilis serostatus                     |                          |                         |         |
| Negative                                | 752 (98.8)               | 253 (98.1)              | 0.3677  |
| Positive                                | 9 (1.2)                  | 5 (1.9)                 |         |
| HSV-2 serostatus                        |                          |                         |         |
| Negative                                | 527 (70.0)               | 185 (72.8)              | 0.3885  |
| Positive                                | 226 (30.0)               | 69 (27.2)               |         |
| **HIV-positive partners (Index Cases) at baseline** | | | |
| History of any drug use                 |                          |                         |         |
| No                                      | 400 (51.9)               | 125 (49.8)              | 0.5569  |
| Yes                                     | 371 (48.1)               | 126 (50.2)              |         |
| History of injecting drug use           |                          |                         |         |
| No                                      | 469 (60.8)               | 149 (59.4)              | 0.6796  |
| Yes                                     | 302 (39.2)               | 102 (40.6)              |         |
| Injecting drug use in past 12 months    |                          |                         |         |
| No                                      | 741 (96.1)               | 234 (93.2)              | 0.0583  |
| Yes                                     | 30 (3.9)                 | 17 (6.8)                |         |
| Syphilis serostatus                     |                          |                         |         |
| Negative                                | 706 (96.8)               | 233 (98.3)              | 0.2339  |
| Positive                                | 23 (3.2)                 | 4 (1.7)                 |         |
| HSV-2 serostatus                        |                          |                         |         |
included in the sensitivity analysis because no seroconverter was found among couples who reported “consistent condom use in past 12 months”. Because reported rates of condom use were so high, stratification analysis on condom use in the past 12 months at follow-up was conducted. All statistical analyses were performed using SAS software (Version 9.11, SAS Institute, USA).

Ethics Statement
This study protocol, including design, subjects recruiting, consent procedure, etc., was reviewed and approved by the Institutional Review Board of the Chinese National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, written informed consents were obtained from all participants, with one copy given to the subject and one copy for study document. Each participant was given compensation of CNY60 (≈USD9), for their time at each study visit.

Results
Characteristics of the cohort at baseline
A total of 1,618 HIV-discordant couples were eligible for the study, 492 did not participate in the baseline survey and 25 did not complete the baseline survey, and a total of 1,101 HIV-negative spouses completed the baseline survey and were enrolled in the study. Of the 1,101 HIV-negative participants, 288 (26.2%) did not return for follow-up visits. Thus, 813 (73.8%) were successfully followed (Figure 1). As shown in Table 1, the two groups (“retained in cohort” vs. “lost to follow-up”) did not differ significantly with respect to most variables. However, of those who were lost to follow-up, a greater proportion of HIV-negative spouses reported less frequent sex in the past 12 months (p = 0.0002) and a greater proportion of HIV-positive partners were not receiving ART (p = 0.0003).

Characteristics of HIV-negative partners. Among those retained in the cohort, the majority of individuals were female (79.5%), aged 39 years or younger (70.2%), illiterate or educated at primary school only (68.9%), and had never used drugs (96.8%). At baseline, 90.9% of participants reported having had sex with their HIV-positive partner and 22.2% reported inconsistent condom use in the past 12 months. At baseline, 1.2% of HIV-negative partners were syphilis-positive, and 30% were HSV-2-positive (Table 1). Ten participants (1.2%) reported having had commercial sex in their lifetime and only two reported having had commercial sex in the past 12 months. Eleven participants (1.4%) reported having had non-commercial, extramarital sex in their lifetime and only one in the past 12 months.

Characteristics of HIV-positive partners (Index Cases). History of drug use was reported by 48.1% of HIV-positive subjects and history of injecting drugs by 39.2%. A total of 30 HIV-positive subjects (3.9%) reported injecting drug use within the past 12 months. The prevalence of syphilis was 3.2% and the prevalence of HSV-2 was 36.4%. Among HIV-positive partners, 47.8% were already receiving ART at baseline. Median CD4 was 399 cells/μl (inter-quartile range [IQR]: 244–568 cells/μl). In terms of viral load, 51.9% had <400 copies/ml, 30.1% had 400–9,999 copies/ml, and 17.9% ≥10,000 copies/ml (See Table 1).

Characteristics of the cohort at the follow-up
Characteristics of HIV-negative partners. As summarized in Table 2, 85.4% of participants reported having had sex with their HIV-positive spouse and 16.6% reported inconsistent condom use in the past 12 months (Table 2). Seventeen participants (2.1%) reported having bought commercial sex in their lifetime. Among them, only one reported having had commercial sex in the past 12 months. Seventeen participants (2.1%) also reported having had non-commercial, extramarital sex in their lifetime, and four reported having had non-commercial extramarital sex in the past 12 months. Ten participants (1.2%) reported having injected drugs in their lifetime, but none reported injecting drugs in the past 12 months.

Characteristics of HIV-positive partners (Index Cases). At the follow-up visit, median CD4 of HIV-positive

| Table 1. Cont. |
|----------------|
| Characteristics | Retained in Cohort N (%) | Lost to Follow-up N (%) | P-value |
| Negative        | 458 (63.6)              | 145 (62.2)              | 0.7042  |
| Positive        | 262 (36.4)              | 88 (37.8)               |         |
| Antiretroviral treatment |                   |                       |         |
| No             | 424 (52.2)              | 186 (64.6)              | 0.0003  |
| Yes            | 389 (47.8)              | 102 (35.4)              |         |
| CD4+ T cell count (cells/μl) |                   |                       |         |
| <200           | 108 (15.3)              | 38 (16.5)               | 0.9618  |
| 200–349        | 187 (26.4)              | 58 (25.2)               |         |
| 350–499        | 170 (24.0)              | 56 (24.4)               |         |
| ≥500           | 243 (34.3)              | 78 (33.9)               |         |
| Median (IQR)   | 399 (244–568)           | 396 (262–564)           |         |
| Plasma HIV viral load (copies/ml) |             |                       |         |
| <400           | 379 (51.9)              | 102 (43.4)              | 0.0719  |
| 400–9,999      | 220 (30.1)              | 80 (34.0)               |         |
| 10,000–49,999  | 30 (4.1)                | 8 (3.4)                 |         |
| ≥50,000        | 101 (13.8)              | 45 (19.2)               |         |
| Overall        | 813 (100.0)             | 288 (100.0)             | -       |

IQR: Inter-quartile range.
doi:10.1371/journal.pone.0077981.t001

Prevention of HIV Transmission in China
Table 2. Comparison of characteristics of HIV-negative and HIV-positive partners at baseline and follow up relative to whether the HIV-positive partner (index case) was on ART or naive to ART among study of HIV discordant couples in rural Yunnan, China, 2009–2011.

| Characteristics                          | At Baseline | At Follow-Up* |
|------------------------------------------|-------------|---------------|
|                                          | Overall N (%) | Index Case On ART N (%) | Index Case ART-NaiveN (%) | χ²-value | P-value | Overall N (%) | Index Case On ART N (%) | Index Case ART-NaiveN (%) | χ²-value | P-value |
| HIV-negative partners                    |             |               |                   |          |        |             |               |                   |          |        |
| Frequency of sex in past 12 months (times/month) |             |               |                   |          |        |             |               |                   |          |        |
| No sex                                   | 73 (9.1)    | 39 (10.1)     | 34 (8.1)          | 1.037    | 0.5953 | 119 (14.6)  | 51 (10.8)     | 68 (19.9)          | 13.117   | 0.0014 |
| 1–3                                      | 314 (39.3)  | 147 (38.1)    | 167 (40.0)        |          |        | 306 (37.6)  | 183 (38.9)    | 123 (36.0)        |          |        |
| 4–30                                     | 417 (51.6)  | 200 (51.8)    | 217 (51.9)        |          |        | 388 (47.7)  | 237 (50.3)    | 151 (44.1)        |          |        |
| Consistent condom use in past 12 months  |             |               |                   |          |        |             |               |                   |          |        |
| No sex                                   | 73 (9.1)    | 39 (10.1)     | 34 (8.1)          | 35.616   | <0.0001 | 119 (14.6)  | 51 (10.8)     | 68 (19.9)          | 20.085   | <0.0001 |
| Yes                                      | 549 (68.3)  | 295 (76.4)    | 254 (60.8)        |          |        | 559 (68.8)  | 352 (74.7)    | 207 (60.5)        |          |        |
| HIV-positive partners (Index Cases)      |             |               |                   |          |        |             |               |                   |          |        |
| CD4 T cell count (cells/µl)              |             |               |                   |          |        |             |               |                   |          |        |
| <200                                     | 108 (15.3)  | 54 (15.6)     | 54 (15.0)         | 17.935   | 0.0005 | 70 (11.6)   | 43 (11.2)     | 27 (12.4)         | 1.397    | 0.7062 |
| 200–349                                  | 187 (26.4)  | 111 (32.0)    | 76 (21.0)         |          |        | 126 (20.9)  | 86 (22.3)     | 40 (18.3)         |          |        |
| 350–499                                  | 170 (24.0)  | 87 (25.1)     | 83 (23.0)         |          |        | 119 (19.7)  | 75 (19.5)     | 44 (20.2)         |          |        |
| ≥500                                     | 243 (34.3)  | 95 (27.3)     | 148 (41.0)        |          |        | 288 (47.8)  | 181 (47.0)    | 107 (49.1)        |          |        |
| Median (IQR)                             | 399 (244–568) | 361 (252–515) | 431 (276–631)     |          |        | 473 (303–674) | 464 (303–675) | 489 (316–658)     |          |        |
| Plasma HIV viral load (copies/ml)        |             |               |                   |          |        |             |               |                   |          |        |
| <400                                     | 379 (51.9)  | 307 (85.0)    | 72 (19.5)         | 313.979  | <0.0001 | 375 (62.8)  | 318 (82.6)    | 57 (26.9)         | 186.028  | <0.0001 |
| 400–9,999                                | 220 (30.1)  | 35 (9.7)      | 185 (50.1)        |          |        | 132 (22.1)  | 42 (10.9)     | 90 (42.4)         |          |        |
| 10,000–49,999                            | 30 (4.1)    | 4 (1.1)       | 26 (7.1)          |          |        | 21 (3.5)    | 2 (0.5)       | 19 (9.0)          |          |        |
| ≥50,000                                  | 101 (13.8)  | 15 (4.2)      | 86 (23.3)         |          |        | 69 (11.6)   | 23 (6.0)      | 46 (21.7)         |          |        |
| Overall                                  | 813 (100)   | 389 (47.8)    | 424 (52.2)        |          |        | 813 (100)   | 471 (57.9)    | 342 (42.1)        |          |        |

IQR: Inter-quartile range.

*A total of 82 HIV-positive partners (index cases) began ART during the follow-up period. At baseline, these individuals were included in the “Naive to ART” category and at follow-up, they were included in the “On ART” category.

doi:10.1371/journal.pone.0077981.t002
Table 3. Univariate and multivariate analyses of risk factors for HIV seroconversion among HIV-negative participants during follow-up HIV discordant couples in rural Yunnan, China, 2009–2011.

| Variables of HIV-negative partners at baseline | Seroconverters | HIV Incidence (per 100 PY) | Unadjusted HR (CI) | P-value | Adjusted HR (CI) | P-value |
|-----------------------------------------------|---------------|----------------------------|-------------------|---------|-----------------|---------|
| Age (years)                                   |               |                            |                   |         |                 |         |
| <30                                           | 8 (47.0)      | 310                        | 2.6               | 1.00    | 1.00            |         |
| 30–39                                         | 7 (41.2)      | 470                        | 1.5               | 0.57    | 0.21–1.58       | 0.2806  |
| ≥40                                           | 2 (11.8)      | 348                        | 0.6               | 0.22    | 0.05–1.02       | 0.0536  |
| Gender                                        |               |                            |                   |         |                 |         |
| Female                                        | 12 (70.6)     | 901                        | 1.3               | 1.00    |                 |         |
| Male                                          | 5 (29.4)      | 226                        | 2.2               | 1.64    | 0.58–4.65       | 0.3529  |
| Education                                     |               |                            |                   |         |                 |         |
| Illiterate or primary school                  | 12 (70.6)     | 781                        | 1.5               | 1.00    |                 |         |
| Junior/middle or high school                  | 5 (29.4)      | 346                        | 1.4               | 0.94    | 0.33–2.66       | 0.9016  |
| Syphilis serostatus                           |               |                            |                   |         |                 |         |
| Negative                                      | 17 (100.0)    | 1071                       | 1.6               | 1.00    |                 |         |
| Positive                                      | 0 (0.0)       | 13                         | 0.0               | 0.00    | 0.00–0.00       | 0.5144  |
| HSV-2 serostatus                              |               |                            |                   |         |                 |         |
| Negative                                      | 12 (70.6)     | 757                        | 1.6               | 1.00    |                 |         |
| Positive                                      | 5 (29.4)      | 317                        | 1.6               | 1.00    | 0.35–2.84       | 1.0000  |
| Variables of HIV-positive partners (Index Cases) at baseline |               |                            |                   |         |                 |         |
| Syphilis serostatus                           |               |                            |                   |         |                 |         |
| Negative                                      | 17 (100.0)    | 999                        | 1.7               | 1.00    |                 |         |
| Positive                                      | 0 (0.0)       | 33                         | 0.0               | 0.00    | 0.00–0.00       | 0.2900  |
| HSV-2 serostatus                              |               |                            |                   |         |                 |         |
| Negative                                      | 11 (64.7)     | 648                        | 1.7               | 1.00    |                 |         |
| Positive                                      | 6 (35.3)      | 370                        | 1.6               | 0.95    | 0.35–2.58       | 0.9254  |
| CD4+ T cell count (cells/µl)                  |               |                            |                   |         |                 |         |
| <200                                          | 2 (11.8)      | 152                        | 1.3               | 1.00    |                 |         |
| 200–349                                       | 3 (17.7)      | 266                        | 1.1               | 0.86    | 0.14–5.17       | 0.8732  |
| 350–499                                       | 6 (35.3)      | 242                        | 2.5               | 1.85    | 0.37–19.16      | 0.4512  |
| ≥500                                          | 6 (35.3)      | 345                        | 1.7               | 1.32    | 0.27–6.55       | 0.7327  |
| Plasma HIV viral load (copies/ml)             |               |                            |                   |         |                 |         |
| <400                                          | 1 (5.9)       | 552                        | 0.2               | 1.00    |                 |         |
| 400–9,999                                      | 7 (41.2)      | 305                        | 2.3               | 12.89   | 1.59–104.78     | 0.0168  |
| 10,000–49,999                                 | 2 (11.8)      | 40                         | 5.0               | 27.29   | 2.47–301.00     | 0.0069  |
| ≥50,000                                       | 7 (41.2)      | 138                        | 5.1               | 27.49   | 3.38–223.39     | 0.0019  |
| Variables of HIV-negative partners at follow-up |               |                            |                   |         |                 |         |
| Frequency of sex in past 12 months (times/month) |               |                            |                   |         |                 |         |
| 1–3                                           | 5 (29.4)      | 435                        | 1.1               | 1.00    |                 |         |
| 4–30                                          | 12 (70.6)     | 524                        | 2.3               | 2.01    | 0.71–5.70       | 0.1896  |
| Consistent condom use in past 12 months       |               |                            |                   |         |                 |         |
| No                                            | 17 (100.0)    | 175                        | 9.7               | 1.00    |                 |         |
| Yes                                           | 0 (0.0)       | 784                        | 0.0               | 0.00    | 0.00–0.00       | <0.0001 |
| Variables of HIV-positive partners (Index Cases) at follow-up |               |                            |                   |         |                 |         |
| ART for HIV-positive partners                 |               |                            |                   |         |                 |         |
| No                                            | 12 (70.6)     | 505                        | 2.4               | 1.00    |                 |         |
| Yes                                           | 5 (29.4)      | 622                        | 0.8               | 0.34    | 0.12–0.97       | 0.0436  |
| Overall                                       | 17 (100.0)    | 1,127                      | 1.5               | -       |                 | -       |

PY: Person years; HR: Hazard ratio; CI: Confidence interval (95%).
*Only those already on ART at baseline or started ART before the midpoint were considered to be receiving ART for the purposes of univariate and multivariate analyses.

1) “No sex” category was excluded because there were no seroconverters among participants who reported having had no sex with spouses in past 12 months at follow-up.
doi:10.1371/journal.pone.0077981.t003
partners overall was 473 cells/µl (IQR: 303–674 cells/µl). In terms of viral load, 62.8% had <400 copies/ml, while 22.1% had 400–9,999 copies/ml and 15.1% had >10,000 copies/ml. A total of 471 (57.9%) HIV-positive partners were receiving ART at follow-up, 82 initiated ART during the follow-up period (See Table 2).

Comparison of discordant couples receiving and not receiving ART

As summarized in Table 2, frequency of sex in the past 12 months (p = 0.0014, follow-up) and consistent condom use in the past 12 months (p<0.0001, baseline and follow-up), were greater among couples given that the HIV-positive partner was ART-experienced. Those partners who were on ART already at baseline were more likely to have CD4≥550 cells/µl than those naïve to ART (p = 0.0005, baseline). HIV-positive partners on ART were more likely to have viral load <400 copies/ml (p<0.0001, baseline and follow-up).

HIV seroconversion among HIV-negative participants

The average follow-up time for the 813 HIV-negative participants retained in the cohort was 1.4 PY. As summarized in Table 3, a total of 17 seroconversions were documented during a total of 1,127 PY of follow-up, resulting in an overall incidence of 1.5 per 100 PY. None of these seroconverters were ever injecting drug users, nor had they reported having had extramarital sex in the past 12 months. HIV genotyping and phylogenetic analysis for the 17 seroconverters and their HIV-infected spouses indicated that the partners of each of the 17 HIV-positive couples not only had the same HIV subtype, but that their viral sequences clustered together in phylogenetic tree analysis. HIV incidence was significantly higher among participants who reported inconsistent condom use (9.7 per 100 PY), and who had HIV-positive partners with viral load >400 copies/ml (2.3 per 100 PY for 400–9,999 copies/ml, 5.0 per 100 PY for 10,000–49,000 copies/ml, 5.1 per 100 PY for >50,000 copies/ml) or had an HIV-positive partner who was not receiving ART (2.4 per 100 PY).

ART, condom use, and HIV seroconversion

Study participants whose HIV-positive partner was receiving ART had a significantly lower rate of HIV seroconversion compared to those with partners who were not receiving ART in both univariate analysis (HR = 0.34, CI: 0.12–0.97; p = 0.0436) and multivariate analysis (HR = 0.30, CI: 0.10–0.86; p = 0.0250) after adjusting for potential confounding variables using Cox proportional hazard model (Table 3). The sensitivity analysis with additional adjustment for plasma viral load showed that the association between ART and HIV seroconversion was not statistically significant (p = 0.6387) (Data not shown).

Stratification analysis of the variable consistent condom use during the past 12 months at follow-up showed that among the 135 participants (175 PY) who reported having had sex without consistent condom use during the past 12 months at follow-up, HIV incidence was 13.0 per 100 PY for those whose HIV-positive partners were not receiving ART, two times higher than those whose partners were receiving ART (6.0 per 100 PY, p = 0.1371) (Table 4). A total of five of 17 seroconversions observed in this study (29.0%), occurred in couples in which the HIV-positive partner was on ART prior to baseline. The characteristics of these couples at both baseline and follow-up are summarized in Table 5. All reported inconsistent condom use and four HIV-positive partners had viral load >10,000 copies/ml at baseline.
Discussion

We have shown that uninfected partners of HIV-positive patients receiving ART have approximately one third of the risk of being infected with HIV compared to those of HIV-positive patients not receiving ART. This finding is consistent with studies from other regions that have indicated effective ART can greatly reduce the likelihood of HIV sexual transmission from infected individuals to their sexual partners [5,8–14]. We find that the HIV incidence among discordant couples who are not receiving ART (2.4 per 100 PY) to be similar to that of injecting drug users (2.3 per 100 PY) [27] and men who have sex with men (2.6 per 100 PY) [17], and in the HPTN 052 study (1.2 per 100 PY) [14], but lower than the incidence rates among discordant couples recently reported in Africa (4.3 per 100 PY and 9.2 per 100 PY) [5,11]. The relatively low overall HIV incidence in our sample may be attributed to higher condom use, lower prevalence of STIs, lower prevalence of high-risk sexual behavior, and/or greater availability of ART.

Our findings provide important new evidence for regular treatment as a prevention strategy and are in direct opposition to the study that previously reported no benefits of ART on reducing HIV seroconversion in China [17]. There are at least two possible explanations for this disparity. First, approximately 80% of the HIV-positive partners in the study by Wang et al. were receiving ART, which may have been a sufficiently high percentage to reduce the power of their statistical analysis. Second, the previous study did not present data on viral load of individuals in their sample population. This may result in misclassification of patients as receiving effective ART, when in reality ART adherence may be low and/or ineffectively suppressing viral load [29]. Despite its limitations, Wang’s study did point out major obstacles to the successful implementation of Treatment as Prevention approach in China, including the difficulties of ensuring consistent, long-term viral suppression, the provision of on-going monitoring of viral load, and the thorough examination of virological failure cases [17,18]. Another challenge we encountered in our study was the high proportion of lost to follow up in the non-ART group. We believe that the issue of the missing group of HIV discordant couples can be partially addressed by initiating ART and/or treatment as prevention early, thereby reducing the risks of HIV transmission.

We found that of the five cases of HIV transmission in couples in which the infected partner was receiving ART, four of the infected partners of these seroconverters had viral load >10,000 copies/ml, suggesting that virological failure may have resulted in these transmission events. Seroconversions of HIV-negative partners despite the HIV-positive partner receiving ART have thus far been observed only in rare instances and have been suggested to perhaps be the result of incomplete suppression of...
viral load in semen or cervicovaginal secretions [7,10,14]. We also noted even among those on ART, there were no obvious changes in CD4 cell counts and plasma HIV viral load from baseline to follow-up visit, suggesting that some of them might have undergone immunologic or virological failure, or had low adherence to ART. These findings highlight the need to regularly monitor the viral load, drug resistance, and adherence counseling status among HIV-positive patients who are receiving ART.

While it is well known that the risk of HIV transmission per coital act depends on a number of behavioral and biological factors, prevention efforts targeted specifically at each of these factors have generated mixed results over the past thirty years [30]. For example, sexual abstinence education has been proved to be ineffective among discordant couples, and many of them would choose to continue to have a normal sexual and reproductive life [31]. Also, while condom use are is proven to be effective in reducing transmission risk [32], the rate of condom use remains low among couples in stable relationships [5,33,34]. As our results indicated, all of the five seroconverters who had an infected partner on ART reported no consistent condom use at follow-up visit, which highlights the importance of emphasizing safe sex education for these HIV-discordant couples, even if the HIV-Positive partner is already on treatment. On the other hand, in the present study, a very high proportion of participants continued to maintain a normal sex life and reported consistency in using condoms. This effect underscores the differences in efficacy between early ART as TasP in controlled clinical trials [14], and regular treatment in practice.

Our study has several limitations. Firstly, we included people engaged in stable, heterosexual, HIV-discordant relationships in rural China, which may be neither representative nor generalizable. Secondly, viral load was only collected and measured at baseline and follow-up, not allowing for observations of changes over time. Thirdly, while none of the seroconverters reported having extramarital sex or injecting drug use, there was no effective measure in place to assess the validity of their claims, and the likelihood of misreporting was not estimated. However, it should be noted that genotype and phylogenetic linkage analysis confirms the partners as the source of infection in our study. Fourthly, questions included in the survey on risk behaviors were limited to HIV-related risk behaviors a participant may have engaged in over the past 12 months, some of the participants did not return for a follow up visit for up to 21 months after baseline. This means there could be up to 9 months of follow-up time which would be potentially left unaccounted for, resulting in information bias. Given this was a relatively short term follow-up study, we assumed that the practice of sexual behaviors among couples, especially the use of condoms, followed a regular pattern during the study period; and will have minimum impact on the study results. Also, couples who reported having no sex in the past 12 months could be due to that crackdowns on illicit drug use, many of them would choose to continue to have a normal sexual and reproductive life and reported consistency in using condoms.

Our study represents a test of the real-life benefit of regular HIV treatment for preventing new HIV infections in serodiscordant couples in rural areas. Despite the fact that we have highlighted some of the major challenges China is faced with in treating and preventing HIV infection, our finding of a 66% reduction in HIV transmission provides compelling evidence in support of implementing of HIV TasP. Application of the findings presented in the study will not only be critical for China as it further develops and expands its national ART program, but will also serve as an example of the effectiveness of this strategy for other developing nations.

Acknowledgments

China National HIV Prevention Study Group Zunyou Wu (NCAIDS, China CDC), Keming Rou (NCAIDS, China CDC), Na He (Fudan University), Wenyuan Yin (NCAIDS China CDC), Jie Xu (NCAIDS, China CDC), Lin Pang (NCAIDS, China CDC), Jianhua Li (Yunnan Institute of Drug Abuse), Xiangdong Ming (Yunnan CDC), Fan Li (Xinjiang CDC), Wei Liu (Guangxi CDC), Lishan Zhang (Sichuan CDC), Laiwei Shen (Guizhou CDC), Minghua Zhuang (Shanghai CDC), Liangliu Feng (Chongqing CDC), Hongbo Zhang (Anhui Medical University), and Yehuan Sun (Anhui Medical University) served as the Research Steering Committee. Zunyou Wu (NCAIDS, China CDC), Keming Rou (NCAIDS, China CDC), Na He (Fudan University), and Haiying Fan (NCAIDS, China CDC) served as the Coordination Team. Na He (Fudan University), Zhihong Fu (Fudan University), Yingying Ding (Fudan University), Manhon Jia (Yunnan CDC), Song Duan (Dehong Prefecture CDC), Yuecheng Yang (Dehong Prefecture CDC), and Yunchua Ye (Dehong Prefecture CDC) served as the Research Implementation Team. Lin Pang (NCAIDS, China CDC) and Enwu Liu (NCAIDS, China CDC) served as the Data Management Team. Hongbo Zhang (Anhui Medical University) and Yehuan Sun (Anhui Medical University) served as the Quality Control and Quality Assurance Team. We thank all patients and spouses who participated in the study, the investigators who enrolled and followed study subjects, Roger Detels and Li Li for their valuable comments and suggestions, Enwu Liu for his invaluable statistical support, and Diane Gu for her editing assistance. The opinions expressed herein reflect the collective views of the co-authors and do not necessarily represent the official position of the China National Health and Family Planning Commission, nor the National Center for AIDS/STD Control and Prevention, Chinese Center for Diseases Control and Prevention.

Author Contributions

Conceived and designed the experiments: NH SD KR ZW. Performed the experiments: NH SD KR ZW. Analyzed the data: YD. Performed the experiments: NH SD YD KR MJ JW YY ZW. Contributed reagents/materials/analysis tools: NH SD YD KR MJ JW YY. Wrote the paper: NH YD JMM JSGM ZW. Contributed to the interpretation of the data critically reviewed several versions of the manuscript and approved the submitted version of the manuscript: ZW NH SD YD KR JMM JM JW YJ JSGM.

References

1. Ministry of Health of the People’s Republic of China, Joint United Nations Program on HIV/AIDS, World Health Organization (2011) 2011 Estimates for the HIV/AIDS epidemic in China. Beijing, China.
2. Lingappa JR, Lambdin D, Boku EA, Ngure K, Kagwama L, et al (2008) Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One 3:e1411.
3. Kumarasamy N, Venkatesh KK, Srikrishnan AK, Prasad L, Balakrishnan P, et al (2010) Risk factors for HIV transmission among heterosexual discordant couples in South India. HIV Med. 11:178–186.
4. Arora P, Nagekarke N, Sgaiet SK, Kumar R, Dhingra N, et al. (2011) HIV, HSV-2 and syphilis among married couples in India: patterns of discordance and concordance. Sex Transm Infect. 87:516–520.
5. Rucagra P, Wandelme S, Aabasa A, Banaana AK, Bahemuka U, et al. (2011) HIV incidence and risk factors for acquisition in HIV discordant couples in Masaka, Uganda: an HIV vaccine preparedness study. PLoS One 6:e24037.
6. Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N (2011) Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 8:CD009153.
7. Granich R, Lo YR, B South A, Victoria M, Baggaley R, et al. (2011) Harnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosis. Curr HIV Res. 9:355–366.
8. Montaner JS, Lima VM, Barrios R, Yip B, Wood E, et al. (2011) Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnosis in British Columbia, Canada: a population-based study. Lancet 376:332–339.

9. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, et al. (2010) Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 5:e11068.

10. Donnell D, Bauten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375:2092–2098.

11. Reynolds SJ, Makumbi F, Nakigozi G, Kagayi J, Gray RH, et al. (2011) HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 25:473–477.

12. Del Romero J, Castillo J, Hernandez V, Rodriguez C, Garcia S (2010) Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ 340:c2205.

13. Melo MG, Santos BR, De Cassia Lira R, Varella IS, Turella ML, et al. (2008) Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis 35:912–915.

14. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365:493–505.

15. Guthrie BL, Choi RY, Liu AY, Mackelprang RD, Rositch AF, et al. (2011) Barriers to antiretroviral initiation in HIV-1-discordant couples. J Acquir Immune Defic Syndr 58: e87–e93.

16. El-Sadr MW, Coburn BJ, Blower S (2011) Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS 25:2295–2299.

17. Wang L, Ge Z, Luo J, Shan D, Gao X, et al. (2010) HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr 55:232–238.

18. Cohen MS (2011) HIV treatment as prevention: in the real world the details matter. J Acquir Immune Defic Syndr 56:e101.

19. Zang CP, Jia ZW, Brown K, Reilly KH, Wang JJ, et al. (2011) Heterosexual risk of HIV-1 infection in China: systemic review and meta-analysis. Chin Med J (Engl) 124:1090–1096.

20. Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, et al. (2011) Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational study. Lancet Infect Dis 11:516–524.

21. Duan S, Shen S, Bulterys M, Jia Y, Yang Y, et al. (2010) Estimation of HIV-1 incidence among five focal populations in Dehong, Yunnan: a hard hit area along a major drug trafficking route. BMC Public Health 10:180.

22. Jia Y, Sun J, Fan L, Song D, Tian S, et al. (2008) Estimates of HIV prevalence in a highly endemic area of China: Dehong Prefecture, Yunnan Province. Int J Epidem 37: 1287–1296.

23. China’s Yunnan Provincial Government (2006) Yunnan Provincial HIV/AIDS Prevention and Treatment Regulations. Kunming, China.

24. Han X, Zhang M, Dai D, Wang Y, Zhang Z, et al. (2007) Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: baseline prevalence and subtype-specific difference. AIDS Res Hum Retrov 23:357–364.

25. Tu Y, Wang MJ, Yao J, Zhu XM, Pan PL, et al. (2009) Human immunodeficiency virus-1 genotypic drug resistance among volunteer blood donors in Yunnan, China. Transfusion 49:1865–1873.

26. Han J, Wang L, Zhang Y, Zhang Q, Fang L, et al. (2009) Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China. Int J STD AIDS 20:249–254.

27. Ruan Y, Qin G, Yin L, Chen K, Qian HZ, et al. (2007) Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS 21:839–846.

28. Ruan Y, Jia Y, Zhang X, Liang H, Li Q, et al. (2009) Incidence of HIV-1, syphilis, hepatitis B, and hepatitis C virus infections and predictors associated with retention in a 12-month follow-up study among men who have sex with men in Beijing, China. J Acquir Immune Defic Syndr 52:604–610.

29. Montaner J, Hogg R (2011) Implications of the Henan province report on the treatment as prevention debate. J Acquir Immune Defic Syndr 56:e101.

30. Boily MC, Baggaley RF, Wang L, Masse B, White RG, et al. (2009) Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9:118–129.

31. Coates TJ, Richter L, Caceres C (2008) Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 372:669–684.

32. Kennedy CE, Medley AM, Sweat MD, O’Reilly R (2010) Behavioural interventions for HIV positive prevention in developing countries: a systemic review and meta-analysis. Bull World Health Organ 88:615–625.

33. Hellion R, Domsell D, Rees H, Cohn C, Mugo N, et al. (2012) Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 12: 19–26.

34. Polis CB, Curtis KM (2015) Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis doi:10.1016/S1473-3099(13)70153-5 (early online publication).